12/28/20
Officials at University of Iowa Health care are participating in a trial for a new COVID-19 vaccine.
The Hospitals and Clinics were a trial site for the Pfizer-BioNTech vaccine earlier this year; the new vaccine comes from Novavax.
The Cedar Rapids Gazette reports that the Novavax vaccine is much more like a traditional vaccine, using technology that developed the current flu vaccines. It will also require two doses, three weeks apart like the Pfizer vaccine.
The UIHC will be recruiting about 250 participants for the trial, aged 18 and older. UIHC Executive Dean Patricia Winokur told the Gazette that researchers are specifically interested in recruiting people at high risk for severe COVID-19 infection, underrepresented populations, and front-line workers.